Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to evaluate the safety and efficacy of PAZ320 when added to oral agents or insulin in patients with type 2 diabetes mellitus

Next Previous
Trial Profile

Study to evaluate the safety and efficacy of PAZ320 when added to oral agents or insulin in patients with type 2 diabetes mellitus

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BTI 320 (Primary) ; Antihyperglycaemics; Insulin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Boston Therapeutics

Most Recent Events

  • 22 Sep 2014 Results published in a Boston Therapeutics media release.
  • 04 Sep 2013 Results have been published in the July/August issue of Endocrine Practice according to a Boston Therapeutics media release. Results were also summarised in the media release.
  • 26 Feb 2013 Results have been published electronically in an abstract ahead of print in Endocrine Practice according to a Boston Therapeutics media release. The full article is expected to be published in the July/August issue of the journal.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top